Search
Multiple Sclerosis Clinical Trials in Naples, FL
A listing of 6 Multiple Sclerosis clinical trials in Naples, FL actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 6 of 6
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Multiple Sclerosis
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
The city of Naples, Florida, currently has 6 active clinical trials seeking participants for Multiple Sclerosis research studies.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
Recruiting
The main objectives of the study are to demonstrate pharmacokinetics (PK) similarity between ABP 692 and Ocrelizumab (US), and ABP 692 and Ocrelizumab (EU), and to demonstrate pharmacodynamics (PD) similarity between ABP 692 and Ocrelizumab reference product (RP) based on assessment of the suppression of new active brain lesions over 24 weeks as assessed by magnetic brain imaging (MRI).
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
07/16/2025
Locations: Aqualane Clinical Research, Naples, Florida
Conditions: Relapsing-remitting Multiple Sclerosis (RRMS)
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
Recruiting
This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥18 years) with RMS, PPMS, or NRSPMS who were previously enrolled in the Phase 2b LTS (LTS16004) or 1 of the 4 Phase 3 tolebrutinib pivotal trials (GEMINI 1 \[EFC16033\], GEMINI 2 \[EFC16034\], HERCULES \[EFC16645\], or PERSEUS \[EFC16035\]).
SUBSTUDY: ToleDYNAMIC substudy
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/04/2025
Locations: Aqualane Clinical Research- Site Number : 8400027, Naples, Florida
Conditions: Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
Recruiting
This study will evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of a new dosage of ofatumumab compared to the approved dosage of ofatumumab followed by extended treatment in participants with relapsing multiple sclerosis.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/04/2025
Locations: Aqualane Clinical Research, Naples, Florida
Conditions: Relapsing Multiple Sclerosis (RMS)
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Recruiting
The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: TG Therapeutics Investigational Trial Site, Naples, Florida
Conditions: Relapsing Multiple Sclerosis, Multiple Sclerosis
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/03/2025
Locations: Aqualane Clinical Research, Naples, Florida
Conditions: Relapsing Multiple Sclerosis
Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
Recruiting
Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/17/2024
Locations: Collier Neurologic Specialists, Naples, Florida
Conditions: Multiple Sclerosis
1 - 6 of 6